Update: A Revolution in the Treatment of Non-Hodgkin's Lymphoma
- 1 January 1998
- journal article
- review article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 13 (4), 213-223
- https://doi.org/10.1089/cbr.1998.13.213
Abstract
The use of monoclonal antibodies (MoAbs) for immunotherapy and radioimmunotherapy has ushered in a new era in the treatment of non-Hodgkin's lymphoma.Keywords
This publication has 30 references indexed in Scilit:
- Cancer and Diabetes: Are There Similarities?Cancer Biotherapy & Radiopharmaceuticals, 1997
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- Barriers to Drug Delivery in Solid TumorsScientific American, 1994
- Effect of lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemiaCancer, 1994
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- A Phase I Escalating-Dose Safety, Dosimetry and Efficacy Study of Radiolabeled Monoclonal Antibody LYM-1Cancer Biotherapy, 1993
- Advantage of Dose Fractionation in Monoclonal Antibody-Targeted RadioimmunotherapyJNCI Journal of the National Cancer Institute, 1990
- A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignanciesHematological Oncology, 1989
- Radioimmunotherapy of human colon carcinoma by 131I‐labelled monoclonal anti‐cea antibodies in a nude mouse modelInternational Journal of Cancer, 1988
- Treatment of B cell malignancies with131I LYM-1 monoclonal antibodiesInternational Journal of Cancer, 1988